Asymmetric dimethylarginine and NO metabolites in patients with acute and chronic coronary heart disease
Aim.То study the levels of asymmetric dimethylarginine (ADMA) and NO metabolites in patients with ST elevation acute coronary syndrome (ACS-ST), as well as in patients with stable effort angina (SEA). Material and methods. The study involved 35 patients: 20 with ACS-ST (mean age 57,4±9,2 years) and...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2009-02-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1137 |
| _version_ | 1797882710372384768 |
|---|---|
| author | A. S. Galyavich E. R. Gaynutdinov |
| author_facet | A. S. Galyavich E. R. Gaynutdinov |
| author_sort | A. S. Galyavich |
| collection | DOAJ |
| description | Aim.То study the levels of asymmetric dimethylarginine (ADMA) and NO metabolites in patients with ST elevation acute coronary syndrome (ACS-ST), as well as in patients with stable effort angina (SEA). Material and methods. The study involved 35 patients: 20 with ACS-ST (mean age 57,4±9,2 years) and 15 with SEA (mean age 57±7,1 years). All participants underwent standard examination and measurement of ADMA and NO metabolite (nitrites, nitrates) concentration in venous blood at admission and after 2 weeks of treatment, with the final examination at 12 months.Results. At baseline, ACS-ST patients demonstrated significant increase in ADMA and reduction in NO metabolites. After 2 weeks of treatment, no significant difference in NO metabolite levels was observed between two groups. Non-significant difference in pre- and post-treatment ADMA concentration was registered in ACS-ST patients, but this difference reached statistical significance in the subgroup of ACS-ST participants without arterial hypertension. The patients who suffered a recurrent fatal myocardial infarction within the next 12 months, demonstrated higher ADMA concentrations than all ACS individuals.Conclusion. ACS-ST patients had increased ADMA levels and reduced NO metabolite concentrations. In treated ACS-ST patients, NO metabolite levels increased. |
| first_indexed | 2024-04-10T03:40:05Z |
| format | Article |
| id | doaj.art-fda9ced9cbfa4ce0847c61a974242e4c |
| institution | Directory Open Access Journal |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| last_indexed | 2024-04-10T03:40:05Z |
| publishDate | 2009-02-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj.art-fda9ced9cbfa4ce0847c61a974242e4c2023-03-13T07:23:16Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252009-02-01813134849Asymmetric dimethylarginine and NO metabolites in patients with acute and chronic coronary heart diseaseA. S. Galyavich0E. R. Gaynutdinov1ГОУ ВПО Казанский государственный медицинский университет РосздраваГОУ ВПО Казанский государственный медицинский университет РосздраваAim.То study the levels of asymmetric dimethylarginine (ADMA) and NO metabolites in patients with ST elevation acute coronary syndrome (ACS-ST), as well as in patients with stable effort angina (SEA). Material and methods. The study involved 35 patients: 20 with ACS-ST (mean age 57,4±9,2 years) and 15 with SEA (mean age 57±7,1 years). All participants underwent standard examination and measurement of ADMA and NO metabolite (nitrites, nitrates) concentration in venous blood at admission and after 2 weeks of treatment, with the final examination at 12 months.Results. At baseline, ACS-ST patients demonstrated significant increase in ADMA and reduction in NO metabolites. After 2 weeks of treatment, no significant difference in NO metabolite levels was observed between two groups. Non-significant difference in pre- and post-treatment ADMA concentration was registered in ACS-ST patients, but this difference reached statistical significance in the subgroup of ACS-ST participants without arterial hypertension. The patients who suffered a recurrent fatal myocardial infarction within the next 12 months, demonstrated higher ADMA concentrations than all ACS individuals.Conclusion. ACS-ST patients had increased ADMA levels and reduced NO metabolite concentrations. In treated ACS-ST patients, NO metabolite levels increased.https://cardiovascular.elpub.ru/jour/article/view/1137асимметричный диметиларгининоксид азотаатеросклерозишемическая болезнь сердца |
| spellingShingle | A. S. Galyavich E. R. Gaynutdinov Asymmetric dimethylarginine and NO metabolites in patients with acute and chronic coronary heart disease Кардиоваскулярная терапия и профилактика асимметричный диметиларгинин оксид азота атеросклероз ишемическая болезнь сердца |
| title | Asymmetric dimethylarginine and NO metabolites in patients with acute and chronic coronary heart disease |
| title_full | Asymmetric dimethylarginine and NO metabolites in patients with acute and chronic coronary heart disease |
| title_fullStr | Asymmetric dimethylarginine and NO metabolites in patients with acute and chronic coronary heart disease |
| title_full_unstemmed | Asymmetric dimethylarginine and NO metabolites in patients with acute and chronic coronary heart disease |
| title_short | Asymmetric dimethylarginine and NO metabolites in patients with acute and chronic coronary heart disease |
| title_sort | asymmetric dimethylarginine and no metabolites in patients with acute and chronic coronary heart disease |
| topic | асимметричный диметиларгинин оксид азота атеросклероз ишемическая болезнь сердца |
| url | https://cardiovascular.elpub.ru/jour/article/view/1137 |
| work_keys_str_mv | AT asgalyavich asymmetricdimethylarginineandnometabolitesinpatientswithacuteandchroniccoronaryheartdisease AT ergaynutdinov asymmetricdimethylarginineandnometabolitesinpatientswithacuteandchroniccoronaryheartdisease |